On January 23, 2026, Ford Robert B., Chairman and CEO of Abbott Laboratories, acquired 18,800 common shares, boosting his total stake to 216,203 shares. This significant insider purchase underscores management’s belief in the company’s long-term prospects, particularly as Abbott navigates challenges in its Nutrition segment while capitalizing on growth in Medical Devices and diagnostics.

Despite recent headwinds from higher manufacturing costs in Nutrition and a modest Q4 revenue shortfall against analyst expectations, Abbott has received a consensus 'Buy' rating. The company forecasts a 7% increase in full-year sales and 10% growth in earnings per share for 2025, driven by sustained double-digit expansion in its Continuous Glucose Monitoring business and early signs of recovery in Nutrition.

Abbott’s streak of 54 consecutive years of dividend increases cements its position among Dividend Kings, offering a 2.2% yield attractive to income investors. Looking ahead, the anticipated closing of the Exact Sciences acquisition in Q2 2026 is expected to add a new cancer-detection vertical, diversifying the portfolio further and enhancing long-term growth potential.